Svelte Medical Systems, Inc. Announces Treatment of First Patient in the DIRECT Drug-Eluting Stent Study
11/8/2011 9:09:43 AM
NEW PROVIDENCE, N.J.--(BUSINESS WIRE)--Svelte® Medical Systems today announced treatment of the first patient in the DIRECT (Direct-on-a-wire Implantation of Rapamycin-eluting stent with bio-Eroding Carrier Technology) study at Auckland City Hospital in Auckland, New Zealand. DIRECT is a First-In-Man, multi-center clinical study designed to assess the feasibility of Svelte’s novel ‘All-In-One’ system, which combines a thin-strut cobalt chromium stent with a fully bio-erodable drug carrier and the well-studied sirolimus (rapamycin) drug, mounted on Svelte’s novel fixed-wire delivery system. The ‘All-In-One’ system is low profile and highly flexible, navigating through the vasculature similar to a traditional guidewire, allowing physicians to ‘direct-stent’ coronary artery lesions and eliminate several steps in their current stenting procedures, thereby reducing procedure time and cost.
comments powered by